(VIANEWS) – ACOMO (ACOMO.AS), SANOFI (SAN.PA), ARCADIS (ARCAD.AS) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up until now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. ACOMO (ACOMO.AS)
80.65% Payout Ratio
Acomo N.V., together with its subsidiaries, engages in sourcing, trading, processing, packaging, and distributing conventional and organic food ingredients and solutions for the food and beverage industry worldwide. It operates through five segments: Spices and Nuts, Edible Seeds, Organic Ingredients, Tea, and Food Solutions. The Spices and Nuts segment provides tropical products, including pepper, nutmeg, desiccated coconut, shelled and unshelled nuts, dried fruits, dehydrated vegetables, herbs, rice crackers, and snack products. Its Edible Seeds segment trades, processes, and distributes edible seeds, such as poppy, sesame, pumpkin, and flax, as well as sunflower seeds comprising in-kernel and shelled for the snack and retail industries; birdseeds for wildlife; and edible seeds to bakery, spice, and confectionery industries. The Organic Ingredients segment provides a range of organic food products and ingredients in various categories, including cocoa, coffee, fruit and vegetables, edible seeds, nuts and dried fruits, oils, and premium juice products. Its Tea segment trades, processes, and distributes through warehouses and blending facilities; and monitors and analyzes market development, and shares insight to customers to meet traditional consumer preferences, which include novel appetites for specialty tea. The Food Solutions segment produces and supplies culinary and functional ingredients, plant-based solutions, wet and dry blends, and spice mixes to food companies; and provides product development, manufacturing, packaging, distribution, and inventory management services. The company was formerly known as Amsterdam Commodities N.V. and changed its name to Acomo N.V. in June 2022. Acomo N.V. was founded in 1908 and is based in Rotterdam, the Netherlands.
Earnings Per Share
As for profitability, ACOMO has a trailing twelve months EPS of €1.55.
PE Ratio
ACOMO has a trailing twelve months price to earnings ratio of 12.63. Meaning, the purchaser of the share is investing €12.63 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.27%.
Yearly Top and Bottom Value
ACOMO’s stock is valued at €19.58 at 07:10 EST, way below its 52-week high of €23.15 and above its 52-week low of €18.06.
Moving Average
ACOMO’s value is under its 50-day moving average of €21.04 and under its 200-day moving average of €20.86.
Volume
Today’s last reported volume for ACOMO is 3093 which is 73.22% below its average volume of 11550.
Sales Growth
ACOMO’s sales growth for the current quarter is negative 3.2%.
More news about ACOMO.
2. SANOFI (SAN.PA)
51.97% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.85.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.47. Meaning, the purchaser of the share is investing €14.47 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.07%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 3.56 and the estimated forward annual dividend yield is 3.61%.
More news about SANOFI.
3. ARCADIS (ARCAD.AS)
51.39% Payout Ratio
Arcadis NV offers design, engineering, and consultancy solutions for natural and built assets in The Americas, Europe, the Middle East, and the Asia Pacific. It operates through Places, Mobility, Resilience, and Intelligence segments. The company offers architectural and urbanism services; and asset management services, such as asset management strategy and planning, asset management decision making and operational optimization, life cycle planning and asset management systems, asset information/condition assessment, risk and review, organization and people, and asset management/O&M. It also provides business advisory services, including asset strategy and performance, business transformation and resiliency, investment and finance, operations and maintenance, and technology and information; contract solutions; cost and commercial management services; and design and engineering solutions for highways, railways, bridges, tunnels, power utilities, water utilities, ports and waterways, geotechnics, architecture, and structures, as well as building mechanical, electrical, and plumbing. In addition, the company offers digital environmental health safety and sustainability, environmental restoration, and project management solutions. Further, it provides mobility solutions for connected highways, intelligent rail and transit, integrated airports, and new mobility; places solutions; resilience solutions, including energy transition, climate adaption, water optimization, enviro socio permitting, sustainable advisory, environmental restoration, and sustainable operations; and water supply and treatment, distribution, resource management, and industrial water and wastewater services. The company was formerly known as Heidemij NV and changed its name to Arcadis N.V. in October 1997. Arcadis NV was founded in 1888 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ARCADIS has a trailing twelve months EPS of €1.44.
PE Ratio
ARCADIS has a trailing twelve months price to earnings ratio of 29.56. Meaning, the purchaser of the share is investing €29.56 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.23%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 34.1%, now sitting on 4.66B for the twelve trailing months.
Sales Growth
ARCADIS’s sales growth for the next quarter is negative 3.2%.
Yearly Top and Bottom Value
ARCADIS’s stock is valued at €42.56 at 07:10 EST, under its 52-week high of €43.70 and way above its 52-week low of €31.02.
Volume
Today’s last reported volume for ARCADIS is 24942 which is 83.44% below its average volume of 150658.
More news about ARCADIS.
4. ITERA (ITERA.OL)
37.91% Payout Ratio
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.82.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 16.71. Meaning, the purchaser of the share is investing kr16.71 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 99.64%.
Yearly Top and Bottom Value
ITERA’s stock is valued at kr13.70 at 07:10 EST, way under its 52-week high of kr16.50 and way higher than its 52-week low of kr10.95.
More news about ITERA.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1% and 1%, respectively.
More news about 1.
